Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 6 min ago
Peer-reviewedCC BYFrontiers in cellular and infection microbiology

Hantaviral therapeutics: life cycle targets and chemotherapeutic interventions

  • Deren Zehra Kocabiyik1
  • Jansen de Araujo2
  • Edison Luiz Durigon3
  • Carsten Wrenger1
  1. 1Unit for Drug Discovery, Department of Parasitology, Institute of Biomedical Sciences, University of São Paulo , ,
  2. 2Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo , ,
  3. 3Institut Pasteur de São Paulo , ,
Read full textPDFDOICite

Abstract

Orthohantaviruses represent a persistent global health threat, being responsible for life-threatening diseases such as Hemorrhagic Fever with Renal Syndrome (HFRS) and Hantavirus Cardiopulmonary Syndrome (HCPS). Despite high case fatality rates and recent outbreaks, there are currently no universally licensed antivirals or vaccines. Clinical management remains heavily reliant on supportive care and repurposed drugs, which often exhibit limited efficacy and dose-limiting toxicities. This review examines rational drug design strategies targeting critical steps in the viral life cycle, specifically Gn/Gc-mediated cellular entry and RNA-dependent RNA polymerase (RdRp)-driven genome replication. We evaluate the current landscape of viral inhibitors, including peptidomimetics, nucleoside analogues, and naturally derived compounds. To accelerate the discovery of novel treatments, we advocate for the integration of modern in silico screening to evaluate extensive chemical and natural product libraries. These broad compound collections offer a structurally diverse and largely untapped reservoir for antiviral development. Ultimately, expanding preclinical testing to include globally neglected variants will be essential to develop broad-spectrum hantaviral therapeutics capable of mitigating future epidemic threats.

Related

  1. Metal-based epigenetic therapeutics in cancer: Mechanisms, targets, and opportunities for overcoming drug resistance
    Julia Astapczyk, Olga Klaudia Szewczyk-Roszczenko, Yegor Vassetzky +1
    Pharmacological ResearchPeer-reviewedCC BY 4.0Full textOncologyHAL
  2. Exercise-based interventions for internet gaming disorder: current evidence, mechanistic rationale, and the augmenting role of serious games and digital therapeutics
    Wentao Liu, Kangle Wang, Minling Yu +1
    Frontiers in Public HealthPeer-reviewedCC BY 4.0Epidemiology & public healthFrontiers
  3. Improving Urology Ward Round Documentation Through Sequential Digital Interventions: A Three-Cycle Quality Improvement Project
    Sohaib Ansari, Samarth Golash, Marina Leonidou +2
    CureusPeer-reviewedCC BYFull textGeneral medicineEurope PMCPMC
  4. Targeting PSMD14 increases chemotherapeutic sensitivity to gemcitabine by inhibiting the WNT/β-catenin pathway and glycolysis in pancreatic cancer.
    Kun Cai, Shiyu Chen, Guoqing Ma +7
    Cell death & diseasePeer-reviewedCC BYFull textOncologyEurope PMCDOAJPMC
  5. Integrated analyses identify MAN1B1 as a candidate regulator of chemotherapeutic tolerance and immunosuppression in bladder cancer
    Mingzhe Jiang, Dong Zhao, Liang Zhang +3
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textSurgery & anaesthesiaCrossrefEurope PMC

Cite

BibTeXRIS
BibTeX
@article{kocabiyik2026hantaviral,
  title = {{Hantaviral therapeutics: life cycle targets and chemotherapeutic interventions}},
  author = {Deren Zehra Kocabiyik and Jansen de Araujo and Edison Luiz Durigon and Carsten Wrenger},
  journal = {Frontiers in cellular and infection microbiology},
  year = {2026},
  month = oct,
  doi = {10.3389/fcimb.2026.1972830},
  url = {https://europepmc.org/article/PMC/PMC13720532},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Hantaviral therapeutics: life cycle targets and chemotherapeutic interventions
AU  - Deren Zehra Kocabiyik
AU  - Jansen de Araujo
AU  - Edison Luiz Durigon
AU  - Carsten Wrenger
PY  - 2026
DA  - 2026/10/16
JO  - Frontiers in cellular and infection microbiology
DO  - 10.3389/fcimb.2026.1972830
UR  - https://europepmc.org/article/PMC/PMC13720532
AB  - Orthohantaviruses represent a persistent global health threat, being responsible for life-threatening diseases such as Hemorrhagic Fever with Renal Syndrome (HFRS) and Hantavirus Cardiopulmonary Syndrome (HCPS). Despite high case fatality rates and recent outbreaks, there are currently no universally licensed antivirals or vaccines. Clinical management remains heavily reliant on supportive care and repurposed drugs, which often exhibit limited efficacy and dose-limiting toxicities. This review examines rational drug design strategies targeting critical steps in the viral life cycle, specifically Gn/Gc-mediated cellular entry and RNA-dependent RNA polymerase (RdRp)-driven genome replication. We evaluate the current landscape of viral inhibitors, including peptidomimetics, nucleoside analogues, and naturally derived compounds. To accelerate the discovery of novel treatments, we advocate for the integration of modern in silico screening to evaluate extensive chemical and natural product libraries. These broad compound collections offer a structurally diverse and largely untapped reservoir for antiviral development. Ultimately, expanding preclinical testing to include globally neglected variants will be essential to develop broad-spectrum hantaviral therapeutics capable of mitigating future epidemic threats.
SN  - 2235-2988
ER  -